Commit Biologics has developed a novel platform technology to harness the power of the complement system, a vital part of the innate immune system. With a unique mechanism of action, the technology has the potential to create a new type of immunotherapy for the treatment of a variety of cancers.
Commit Biologics is a biotech spin-out from Aarhus University founded in 2021. The Commit team combines expertise in antibody development and complement research to refine the BiCE™ technology. The team has strong academic (highly ranked publications, e.g. Nature, Cell and Science), industrial (Alexion, J&J, Argenx and Complement Pharma) and international experience.
Established in 2022.
